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Abstract
Background: Pluripotency, the capacity for indefinite self-renewal and differentiation into diverse
cell types is a unique state exhibited by embryonic stem (ES) cells. Transcriptional regulators, such
as Oct4, are critical for pluripotency, but the role of epigenetic modifiers remains to be fully
elucidated.
Results:  Here, we show that ERG-associated protein with SET domain (ESET), a histone
methyltransferase enzyme, maintains pluripotency through repression of Cdx2, a key
trophectoderm determinant, by histone H3 lysine 9 trimethylation (H3K9me3) of the promoter
region. Notably, this repression is mediated through the synergistic function of small ubiquitin-
related modifier (SUMO)ylated ESET and Oct4. ESET localises to the promyelocytic leukaemia
(PML) nuclear bodies and is SUMOylated in ES cells. Interaction of ESET with Oct4 depends on a
SUMO-interacting motif (SIM) in Oct4, which is critical for the repression of Cdx2.
Conclusion: Loss of ESET or Oct4 results in strikingly similar phenotypes both in ES cells with
their differentiation into trophectoderm cells, and in early embryos where there is a failure of
development of the pluripotent inner cell mass (ICM) of blastocysts. We propose that SUMOylated
ESET-Oct4 complex is critical for both the initiation and maintenance of pluripotency through
repression of differentiation, particularly of the trophectoderm lineage by epigenetic silencing of
Cdx2.
Background
ERG-associated protein with SET domain (ESET), also
known as SET domain bifurcated 1 (SETDB1), is a histone
methyltransferase that catalyses a repressive mark on
euchromatin by mediating histone 3 lysine 9 trimethyla-
tion (H3K9me3) [1,2]. The ESET protein contains a Tudor
domain, a methyl-CpG binding domain and a bifurcated
SET domain that is responsible for its catalytic activity [3].
Proteins that associate with ESET are mainly corepressors
[1,4-7], in agreement with its repressive role. ESET is criti-
cal for very early development since the Eset-null embryos
die at the peri-implantation stage with defective develop-
ment of the inner cell mass (ICM), from which no embry-
onic stem (ES) cells could be derived [8]. The Eset-null
phenotype is similar to that of Oct4-null embryos [9] but
the basis for this is unknown. We decided to address this
question by investigating the role of ESET in the ICM-
derived pluripotent ES cells.
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ERG-associated protein with SET domain (ESET)-depleted embryonic stem (ES) cells differentiate towards the trophectoderm  lineage Figure 1
ERG-associated protein with SET domain (ESET)-depleted embryonic stem (ES) cells differentiate towards 
the trophectoderm lineage. (a) Western blot shows downregulation of ESET and histone 3 lysine 9 trimethylation 
(H3K9me3) in Eset knockdown ES cells at day 3 of short hairpin RNA (shRNA) transfection. Tubulin and H3K4me2 served as 
loading control. (b) Alkaline phosphatase staining of Eset knockdown (right panel) and control (left panel) ES cells after 7 days 
of shRNA transfection. (c) Morphology of fluorescence-activated cell sorting (FACS)-sorted Eset knockdown (right panel) and 
control (left panel) ES cells at day 5 of shRNA transfection. Scale bar, 50 μm. (d) Gene expression levels in Eset knockdown ES 
cells relative to control cells after normalising against Gapdh, a house keeping gene. Error bars, standard deviation (SD) of three 
technical replicates. (e) Images of three representative colonies from three different wells of control (top panel) and Eset 
knockdown (bottom) ES cells which were purified by FACS at day 3 of shRNA transfection followed by 4 days of culture in 
medium that is conducive for development of trophectoderm cells (TS medium). Cdx2-positive cells are labelled in red. Nuclei 
are labelled in blue. Scale bar, 100 μm.
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Results and Discussion
ESET-depleted ES cells differentiate towards the 
trophectoderm lineage
To investigate the role of ESET in ES cells, we induced
knockdown of Eset using a short hairpin RNA (shRNA)-
expressing vector that contains an enhanced green fluores-
cent protein (EGFP) reporter (Figure 1a). An empty vector
was used as a control. At 7 days following transfection of
Eset shRNA, we observed a dramatic loss of pluripotent ES
cells as judged by a marked reduction in the number of
alkaline phosphatase positive cells (Figure 1b, Additional
file 1). To visualise the morphology of the knockdown
cells, EGFP-positive cells were purified by fluorescent acti-
vated cell sorting (FACS), 24 h after transfection and cul-
tured in ES medium for 2 to 4 days (Figure 1c, Additional
file 1). Notably, ES cells transfected with Eset  shRNA
appeared flat and differentiated, which was clearly distinct
from control ES cells, which formed compact colonies
(Figure 1c). This experiment demonstrates that ESET is
important for the maintenance of undifferentiated ES
phenotype.
Next, 5 days after transfection of Eset shRNA, we carried
out reverse transcription quantitative polymerase chain
reaction (Q-PCR) analysis to determine the precise conse-
quences of Eset  knockdown. Concomitant with the
change in the phenotype in ESET-depleted ES cells, we
found downregulation of pluripotency-specific genes,
including Oct4, Nanog and Sox2. At the same time, we
detected upregulation of genes associated with differenti-
ation, including, Cdx2, Hand1, Dlx3, Ets2, Fgf5 and Gata6
(Figure 1d). Notably, this response is similar to that trig-
gered by the knockdown of Oct4 in ES cells, where genes
associated with the trophectoderm lineage, such as Cdx2
and the primitive endoderm lineage, such as Gata6 are
upregulated [10]. Thus, apart from the failure of ICM
development and pluripotent cells in early embryos fol-
lowing the loss of either Eset [8] or Oct4 [9], the response
of ES cells to the loss of these two genes is also compara-
ble.
The upregulation of trophectoderm-specific genes is of
particular interest as mouse ES cells have a low propensity
to differentiate into trophectoderm cells [11]. This is, at
least in part, because Oct4 and Cdx2 induce reciprocal
inhibition to achieve a mutually exclusive expression in
the pluripotent and the trophectoderm lineages, respec-
tively [12]. Since Eset knockdown evidently exhibits a sim-
ilar outcome as Oct4  knockdown in ES cells, we
investigated whether ESET, like Oct4, might also play a
role in repressing trophectoderm differentiation. We
tested this possibility by investigating whether ESET-
depleted ES cells could give rise to trophectoderm cells. To
do this, we cultured ESET-depleted ES cells in a medium
that is conducive for development of trophectoderm cells
(henceforth called TS medium) [13]. Notably, Cdx2-posi-
tive cells were observed in about 40% of Eset knockdown
cells after 4 days of culture in TS medium (Figure 1e). By
contrast, the majority of EGFP-negative cells cultured in
the TS medium, which represents a concurrent control,
were negative for Cdx2, except for a few cells that are occa-
sionally positive (less than 1% of total cells), which arise
spontaneously when ES cells are exposed to TS medium.
The heterogeneity of expression of Cdx2 in ESET-depleted
ES cells suggests that, apart from the trophectoderm cells,
these ESET-depleted cells may differentiate into other lin-
eages. Nevertheless, ESET-depleted ES cells clearly have a
propensity to differentiate towards the trophectoderm lin-
eage, a response that is uncharacteristic of normally differ-
entiating ES cells. To gain mechanistic insight on the role
of Eset in regulating pluripotency of ES cells, we decided
to focus our analysis on Cdx2, since this is an early and a
key determinant of the trophectoderm lineage [14].
ESET-mediated H3K9me3 represses Cdx2 in ES cells
Since the loss of Eset from ES cells results in the upregula-
tion of Cdx2 at the mRNA and protein levels, we reasoned
that Cdx2 might be repressed by ESET-mediated epige-
netic modification at its promoter region via H3K9me3.
To test for this possibility, we first performed chromatin
immunoprecipitation (ChIP) for H3K9me3 at the Cdx2
promoter region in wild-type ES cells. We detected
H3K9me3 marks that were spread throughout the 5 kb
region surrounding the transcription start site of Cdx2
gene (Figure 2a, b, Additional file 2). In contrast,
H3K9me3 levels were not enriched at the promoter region
of Oct4 gene, which unlike Cdx2 is transcriptionally active
in ES cells (Figure 2a, b).
To investigate whether ESET is the histone methyltrans-
ferase responsible for H3K9me3 modification at the Cdx2
promoter region, we performed ChIP analysis on ES cells.
H3K9me3 was detected at the Cdx2 promoter region, but
this signal was downregulated in ESET-depleted cells by
an average of 40% to 50% compared to control cells (Fig-
ure 2c, Additional file 2). This observation was confirmed
by Q-PCR analysis using primers C1 and C2 (Figure 2d).
As an additional control, we also analysed the H3K9me3
at the major satellite region that is known to be mediated
by Suv39h1/2, a histone methyltransferase that governs
H3K9me3 at the pericentric heterochromatin region
[15,16]. In contrast to the observations on the Cdx2 pro-
moter region, H3K9me3 levels at the major satellite
region were unaffected in ESET-depleted ES cells (Figure
2c, Additional file 2). These results suggest that the
H3K9me3 marks at the Cdx2 promoter region were most
likely mediated by ESET.
To further confirm that ESET mediates H3K9me3 at the
Cdx2  promoter region in ES cells, we performed ChIPEpigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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Figure 2 (see legend on next page)Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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using an anti-ESET antibody. We detected enrichment of
ESET on Cdx2 promoter with a peak at the region imme-
diately upstream of the transcription start site, which was
amplified by primer C7 (Figure 2e). Collectively, these
results demonstrate that ESET-mediated H3K9me3
represses Cdx2 in ES cells.
Oct4 and ESET synergistically repress Cdx2
Next, we considered whether Oct4 and ESET act synergis-
tically to repress Cdx2 since loss of function of Eset and
Oct4  generate similar phenotypes, both during early
embryonic development [8,9], and in ES cells, as
described above. First, we confirmed that Oct4 is enriched
on Cdx2  promoter in wild-type ES cells (Figure 3a) as
reported previously [17]. Notably, Oct4 is enriched at the
same region that is bound by ESET (Figure 2e), suggesting
that both factors might coregulate Cdx2. To address this
possibility, we used ZHBTc4 ES cells that contain a tetra-
cycline regulatable Oct4  allele [18]. Depletion of Oct4
from these ES cells following addition of tetracycline to
the culture medium results in the induction of Cdx2 after
2 days (Figure 3b). To analyse the effect of Oct4 depletion
on the binding of ESET to Cdx2 promoter, we performed
ChIP analysis on ZHBTc4 ES cells at day 1 of tetracycline
treatment when ESET expression was not yet affected by
the depletion of Oct4 (Figure 3b). As expected, Oct4 bind-
ing on the Cdx2 promoter was downregulated by 90% in
Oct4-depleted ES cells (Figure 3c). Notably, this was
accompanied by downregulation of ESET binding on the
Cdx2 promoter by 30% (Figure 3c). Furthermore, down-
regulation of ESET binding was coupled with the decline
of H3K9me3 levels at the Cdx2 promoter region (Figure
3d). We further verified that the binding of ESET to Cdx2
promoter is dependent on Oct4 by performing ChIP
experiments in ZHBTc4 ES cells overexpressing haemag-
glutinin (HA)-tagged ESET (Additional file 3). In this
experiment, tetracycline was first added to ZHBTc4 cells to
initiate loss of Oct4, followed 1 day later by transfection
of HA-tagged ESET, followed by a ChIP experiment 1 day
further on using an anti-HA antibody. The results show
that ESET binding to Cdx2 promoter decreased by 40%
confirming that the loss of Oct4 affects the binding of
ESET to Cdx2 promoter. Taken together, these results sug-
gest that ESET and Oct4 likely cooperate to repress Cdx2,
which is consistent with the observation that depletion of
either ESET or Oct4 leads to upregulation of Cdx2.
Since Cdx2 is a known target of Oct4 [12,17,19], it is pos-
sible that Oct4 may interact with ESET to repress Cdx2. To
test for this possibility, we coexpressed Oct4 and ESET in
293T cells and found that ESET coimmunoprecipitated
with Oct4 (Additional file 3). To further investigate which
domain of ESET interacts with Oct4, we generated two
deletion constructs; HA-ESET-ΔSET and HA-ESET-ΔTudor
(Additional file 3). Interestingly, when we coexpressed
either HA-ESET-ΔSET or HA-ESET-ΔTudor with Oct4,
both mutants were able to coimmunoprecipitate with
Oct4 (Additional file 3), suggesting that ESET and Oct4
form a complex through bridging proteins, or that ESET
associates with Oct4 through at least two different sites.
We also performed immunoprecipitation of endogenous
ESET in ES cells using an anti-ESET antibody and found
that Oct4 was coimmunoprecipitated independently of
DNA, albeit at a low level and only when immunoprecip-
itation was carried out under mild conditions (Figure 3e
and Additional file 4). However, in the reciprocal immu-
noprecipitation experiment using an anti-Oct4 antibody,
we noticed that immunoprecipitation of endogenous
Oct4 not only precipitated the expected ESET protein of
180 kDa, but also ESET proteins of higher molecular
weight, which may be post-translationally modified ESET
proteins (Figure 4e, lane 7, top panel and Additional file
4). We therefore sought to investigate these modified
ESET proteins.
ERG-associated protein with SET domain (ESET)-mediated histone 3 lysine 9 trimethylation (H3K9me3) represses Cdx2 in  embryonic stem (ES) cells Figure 2 (see previous page)
ERG-associated protein with SET domain (ESET)-mediated histone 3 lysine 9 trimethylation (H3K9me3) 
represses Cdx2 in embryonic stem (ES) cells. (a) Chromatin immunoprecipitation (ChIP) primers C1 to C10 used to 
detect enrichment of H3K9me3 on Cdx2 promoter (left). Primers O1 of Oct4 promoter served as a negative control (right). 
The numbers below the bars indicate distance from transcription start site (TSS) in base pairs (bp). (b) Quantitative polymer-
ase chain reaction (Q-PCR) analysis of the enrichment of H3K9me3 at different positions along Cdx2 promoter region relative 
to the Oct4 promoter region after normalising against H3 ChIP and IgG controls. Primers C4 and C6 were not suitable for Q-
PCR analysis. Error bars, standard deviation (SD) of three technical replicates. (c) Carrier ChIP semiquantitative PCR analysis 
of H3K9me3 at the Cdx2 promoter and major satellite regions of fluorescence-activated cell sorting (FACS)-sorted Eset knock-
down ES cells relative to control cells after normalising against their respective input and IgG controls. Primers C6 and C7 
were not suitable for carrier ChIP analysis. Error bars, SD of three independent experiments. (d) Q-PCR analysis of the levels 
of H3K9me3 at region C1 and C2 of the Cdx2 promoter in Eset knockdown ES cells relative to control cells after normalising 
against their respective input and IgG controls. Error bars, SD of three independent experiments. (e) Q-PCR analysis of the 
enrichment of ESET on different positions along the Cdx2 promoter relative to the Oct4 promoter after normalising against 
their respective input and IgG controls. Error bars, SD of three technical replicates.Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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ESET localises to promyelocytic leukaemia (PML) nuclear 
bodies and is post-translationally modified by small 
ubiquitin-related modifier (SUMO)
We had noted that ESET has a very striking pattern of sub-
cellular localisation in ES cells, where it is mainly found
in punctate foci specifically within the euchromatin
region as indicated by the absence of 4',6-diamidino-2-
phenylindole (DAPI) staining (Figure 4a). Notably, we
found that these ESET punctate foci overlap with PML
nuclear bodies (Figure 4b). Coimmunoprecipitation
experiments in 293T (Additional file 5) and ES cells under
mild conditions (Figure 4c and Additional file 4) show
that ESET interacts with PML. PML nuclear bodies are of
interest because these are highly organised structural and
functional domains that are composed of the PML protein
and various other proteins that are involved in different
biological functions [20,21]. Post-translational modifica-
tion of PML through addition of SUMOs is pivotal for the
formation of PML nuclear bodies [22,23], and many pro-
teins found in the PML nuclear bodies are SUMOylated
[24,25]. Since ESET colocalises to PML nuclear bodies and
interacts with PML in ES cells, we investigated whether
ESET undergoes SUMOylation.
Oct4 and ERG-associated protein with SET domain (ESET) synergistically repress Cdx2 Figure 3
Oct4 and ERG-associated protein with SET domain (ESET) synergistically repress Cdx2. (a) Quantitative 
polymerase chain reaction (Q-PCR) analysis of the enrichment of Oct4 on different positions along the Cdx2 promoter relative 
to the least enriched region (C3) after normalising against their respective input and IgG controls. Error bars, standard devia-
tion (SD) of three technical replicates. (b) Western blot shows upregulation of Cdx2 and downregulation of ESET upon deple-
tion of Oct4 at day 2 of tetracycline (Tc) treatment of ZHBTc4 embryonic stem (ES) cells. (c) Q-PCR analysis of the levels of 
Oct4 and ESET enrichment at region C7 of the Cdx2 promoter in ZHBTc4 ES cells treated with Tc for 1 day relative to 
untreated cells after normalising against their respective input. Error bars, SD of three independent experiments. (d) Carrier 
chromatin immunoprecipitation (ChIP) Q-PCR analysis of the levels of histone 3 lysine 9 trimethylation (H3K9me3) at region 
C1 and C2 of the Cdx2 promoter in ZHBTc4 ES cells treated with Tc for the indicated days relative to untreated cells after 
normalising against their respective input and IgG controls. Error bars, SD of three independent experiments. (e) ES cell 
lysates were immunoprecipitated (IP) with anti-ESET antibody (kind gift of HH Ng; see text) under mild conditions in digitonin-
containing buffer and subjected to western blotting (WB) with the antibodies indicated. Rabbit IgG was used as a negative con-
trol.
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Figure 4 (see legend on next page)
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To test this hypothesis, HA-ESET and Flag-SUMO-1 were
cotransfected in 293T cells and cell lysates were subjected
to immunoprecipitation in the presence of N-ethylmale-
imide (NEM), an inhibitor of SUMO isopeptidases. When
cell lysate was immunoprecipitated with anti-HA anti-
body (to immunoprecipitate ESET) and immunoblotted
with anti-Flag antibody (to visualise SUMOylated ESET),
we observed several slower migrating ESET proteins,
which may be indicative of different degrees of SUMOyla-
tion of ESET protein (Figure 4d). This result suggests that
ESET may be SUMOylated in ES cells and that the high
molecular weight ESET proteins that interact with Oct4
are probably SUMOylated forms of ESET proteins.
To confirm that the various larger forms of ESET proteins
being immunoprecipitated by Oct4 are SUMOylated
ESET, we performed immunoprecipitation of ESET from
ES cell lysate in the presence of NEM. We found that ESET
was indeed SUMOylated as shown by immunoblotting
with anti-ESET and anti-SUMO-1 antibodies (Figure 4e,
lane 4). Similarly, the immunoprecipitant from anti-
SUMO-1 antibody (Figure 4e, lane 5) produced the same,
high molecular weight bands as observed with the immu-
noprecipitant from either anti-ESET (Figure 4e, lane 4) or
anti-Oct4 (Figure 4e, lane 3) antibodies. More impor-
tantly, these bands were less prominent when immuno-
precipitation was carried out without the addition of NEM
(Figure 4e, lanes 6 to 9). In addition, the higher molecular
weight ESET proteins corresponding to SUMOylated ESET
were also observed with the immunoprecipitant from
anti-PML antibody (Additional files 4 and 5). Collec-
tively, these data confirmed that the higher molecular
weight ESET proteins that interact with Oct4 are
SUMOylated ESET suggesting that SUMOylated ESET-
Oct4 interaction is required for the repression of Cdx2.
Consistent with this, we show by ChIP experiments that
SUMO-1 is highly enriched on Cdx2 promoter (Figure 4f),
most notably at the region that was amplified by primer
C7, which happens to be the region where ESET was also
most enriched (Figure 2e). The presence of SUMO-1 and
ESET at the same region on Cdx2 promoter suggests that
SUMOylated ESET binds to Cdx2, although we cannot
rule out a possibility that other SUMOylated proteins
might be present in the same region.
Delocalisation of ESET from PML nuclear bodies enhances 
the interaction of SUMOylated ESET and Oct4
We then considered whether the localisation of ESET to
the PML bodies is crucial for its interaction with Oct4. To
do this, we performed shRNA knockdown of Pml in ES
cells. Notably, we found that ESET punctate foci were lost
in PML-depleted ES cell nuclei (Figure 5a, white border),
although the ESET protein levels remained unaltered (Fig-
ure 5c: compare lanes 1 and 2). Furthermore, confocal
images suggested that the ESET protein was now uni-
formly dispersed throughout the ES nuclei. Notably, this
delocalisation of ESET from PML nuclear bodies increased
its interaction with Oct4 (Figure 5b, lane 4). In the recip-
rocal immunoprecipitation experiments, more
SUMOylated ESET was found to associate with Oct4 (Fig-
ure 5c, lanes 4 and 6). This observation suggests that the
scaffold composed of PML regulates the interaction
between SUMOylated ESET and Oct4, perhaps by modu-
lating the levels of SUMOylated ESET. These results are
consistent with our observations that Oct4 preferentially
interacts with SUMOylated ESET.
SUMO-interacting motif (SIM) of Oct4 is crucial for the 
interaction with ESET and the repression of Cdx2
To further confirm the interaction of Oct4 and
SUMOylated ESET, we attempted to map the sumoylation
sites of ESET and the SIM in Oct4. The consensus
sumoylation site sequence is ¬-Lys-X-Glu/Asp (¬KxE/D),
where ¬ is a large hydrophobic amino acid and X is any
amino acid [26]. Based on the sumoylation prediction
software, SUMOplot (Abgent, San Diego, California,
USA), many putative sumoylation sites were found in the
ERG-associated protein with SET domain (ESET) localises to promyelocytic leukaemia (PML) nuclear bodies and is post-trans- lationally modified by small ubiquitin-related modifier (SUMO) Figure 4 (see previous page)
ERG-associated protein with SET domain (ESET) localises to promyelocytic leukaemia (PML) nuclear bodies 
and is post-translationally modified by small ubiquitin-related modifier (SUMO). (a) ESET (red) localises to dis-
tinct, punctate foci in euchromatin regions, as indicated by the absence of DAPI (blue) staining in embryonic stem (ES) cells. 
Scale bar, 3 μm. (b) ESET (red) localises to distinct, punctate foci that overlaps with PML nuclear bodies (green) in ES cells. 
Nuclei are labelled in blue. Scale bar, 5 μm. (c) ES cell lysates were immunoprecipitated (IP) with anti-ESET antibody (kind gift 
of HH Ng; see text) under mild conditions in digitonin-containing buffer and subjected to western blotting (WB) with the anti-
bodies indicated. Rabbit IgG was used as a negative control. (d) Western blot analysis of coimmunoprecipitation experiment in 
293T cells transfected with haemagglutinin (HA)-ESET and/or Flag-SUMO-1. S-ESET represents SUMOylated ESET. (e) ES cell 
lysates were immunoprecipitated (IP) with the indicated antibodies in NP40-containing buffer either in the presence or absence 
of N-ethylmaleimide (NEM) and subjected to western blotting (WB) using 4% to 15% Tris-HCl gradient gel. A rabbit anti-HA 
antibody was used as negative control. (f) Quantitative polymerase chain reaction (Q-PCR) analysis of the enrichment of 
SUMO-1 on different positions along Cdx2 promoter relative to the least enriched region (C5) after normalising against their 
respective input and IgG controls. Error bars, standard deviation (SD) of three technical replicates.Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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Figure 5 (see legend on next page)
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ESET protein (Additional file 6). This is consistent with
our observation that SUMOylated ESET exhibited multi-
ple bands when immunoprecipitated with Oct4. Further-
more, this would also explain why both the Tudor
domain-containing and SET domain-containing frag-
ments of ESET were found to interact with Oct4 (Addi-
tional file 3). Nevertheless, the presence of a large number
of putative sumoylation sites in ESET complicates their
functional analysis through mutation of these sites. How-
ever, only one putative SIM was found in Oct4 (Figure
6a). We thus focussed our studies on investigating the
Oct4 SIM.
Proteins that contain the SIM with the consensus Val/Ile-
X-Val/Ile-Val/Ile (V/I-X-V/I-V/I) in which X is any amino
acid, have a high propensity to interact non-covalently
with SUMOylated proteins [27-30]. An inverse SIM
(amino acids 266-VVRV-269) was found in Oct4 (Figure
6a). Importantly, when this SIM was mutated in Oct4
(Oct4-ΔSIM), the interaction with ESET was abrogated
(Figure 6b, lane 2). This result shows that the SIM of Oct4
is crucial for SUMOylated ESET-Oct4 interaction. The pre-
cise nature of this interaction remains to be elucidated.
We then considered if the SIM of Oct4 is functional in the
repression of Cdx2. We investigated this possibility by
substituting the endogenous Oct4 in ZHBTc4 ES cells with
exogenous Oct4-ΔSIM. Since the SIM of Oct4 is critical for
the interaction with ESET, we anticipated that Cdx2
repression would be less effective in cells that express
Oct4-ΔSIM compared to cells that express wild-type Oct4.
Indeed, this was the case. In control ZHBTc4 ES cells
treated with tetracycline, Cdx2 was upregulated concomi-
tant with the depletion of Oct4 (Figure 6c, lane 2). When
these cells were supplied with exogenous Oct4 (Figure 6c,
lane 3), the upregulation of Cdx2 was also impeded even
though the level of transiently expressed exogenous Oct4
was on average about 10% of the endogenous level in
untreated ES cells (Figure 6c, middle panel). However,
when Oct4-ΔSIM was supplied instead of wild-type Oct4
(Figure 6c, lane 4) at a comparable level, Cdx2 expression
was elevated, notably to a level that approaches the Cdx2
expression levels induced by the lack of Oct4 (Figure 6c,
lane 2). This suggests that the difference in the outcome of
response to Oct4 or Oct4-ΔSIM on the repression of Cdx2
in the ES cells, might be due to the nature of the repressor
complexes that it recruits through its SIM, as Oct4-ΔSIM is
able to bind DNA (Additional file 7). It is possible that
Oct4 may interact with SUMOylated ESET through the
subunits of the transcriptional repression complexes such
as HDAC2 [31,32]. We note that Gata6, a primitive endo-
derm-specific gene, as well as Hand1 and Dlx3 that were
upregulated in Eset knockdown ES cells (Figure 1d), were
similarly repressed by Oct4 and resistant to repression by
Oct4-ΔSIM (Additional file 7). These data suggest that
SUMOylated ESET-Oct4 complex may act to repress genes
other than Cdx2. It is equally likely that ESET might inter-
act with other transcription factors to repress a different
subset of genes in ES cells. Further work is also required to
delineate how Oct4 functions in ES cells to discriminate
between its role both as an activator, and as a repressor of
genes through ESET-Oct4 complex.
Conclusion
We have uncovered an important epigenetic mechanism
that maintains pluripotency by preventing differentiation
of ES cells, notably into trophectoderm cells. The Oct4-
ESET mediated H3K9me3 epigenetic modification
involved in the repression of Cdx2 may affect other genes,
including Gata6, to underpin pluripotency. The synergis-
tic action of Oct4 and ESET could also explain the previ-
ously described observation that Oct4 regulates
expression of Cdx2 [12]. The SIM of Oct4 is apparently
critical for the interaction of ESET and Oct4, which high-
lights the importance of this motif in forming an effective
SUMOylated ESET-Oct4 repressive complex. Since ESET,
like Oct4 is a maternally inherited protein in the oocyte
[8], they may also be critical for the establishment  of
Delocalisation of ERG-associated protein with SET domain (ESET) from promyelocytic leukaemia (PML) nuclear bodies pro- motes the interaction of small ubiquitin-related modifier (SUMO)ylated ESET and Oct4 Figure 5 (see previous page)
Delocalisation of ERG-associated protein with SET domain (ESET) from promyelocytic leukaemia (PML) 
nuclear bodies promotes the interaction of small ubiquitin-related modifier (SUMO)ylated ESET and Oct4. (a) 
In PML (green)-depleted embryonic stem (ES) cells (white border), ESET (red) punctate foci were delocalised from PML 
nuclear bodies. Nuclei are labelled in blue. Scale bar, 3 μm. Cultures also contain cells which were not depleted of PML, where 
ESET exhibit punctate foci (arrow heads) associated with PML bodies. (b) ES cells transfected with Pml short hairpin RNA 
(shRNA) for 4 days were immunoprecipitated (IP) with anti-ESET antibody (kind gift of HH Ng; see text) under mild conditions 
in buffer containing digitonin and ethidium bromide, and were subjected to western blotting (WB) with the antibodies indi-
cated. Note that more Oct4 is precipitated by ESET in Pml knockdown ES cells (*lane 4, top panel). Asterisk (lane 3, middle 
panel) indicates PML being precipitated by ESET in control cells transfected with an empty vector but not in Pml knockdown ES 
cells (compare with lane 4, middle panel). (c) ES cells transfected with Pml shRNA for 4 days were immunoprecipitated (IP) 
with anti-Oct4 antibody in buffer containing NP40, N-ethylmaleimide, and ethidium bromide and subjected to WB using 4% to 
15% Tris-HCl gradient gel. More SUMOylated ESET was precipitated by Oct4 in two independent experiments (Exp 1 and Exp 
2) in Pml knockdown cells as indicated (*; lane 4 and 6, top panel).Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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pluripotent cells in the ICM, at least in part through
repression of Cdx2 (Figure 7). Notably, the loss of ESET or
Oct4 results in the loss of the pluripotent ICM [8,9]. Fur-
thermore, disruption of the SUMO pathway by the inacti-
vation of the SUMO E2-conjugating enzyme Ubc9  is
detrimental to the development of the ICM [33]. The use
of a conditional allele of Eset  will address the precise
developmental role of this gene in the future.
SUMOylated ESET-Oct4 interaction is probably pivotal
for both the establishment of pluripotency in the ICM and
its maintenance in ES cells.
Methods
RNAi constructs and transfection
shRNA oligonucleotides were cloned into the BglII and
HindIII sites of the pSuper.puro vector (Oligoengine, Seat-
tle, WA, USA). Sequences for Eset shRNA which has been
described previously [5] are 5'-
GATCCCCGATGTGAGTGGATATATCGTTCAAGAGAC-
Small ubiquitin-related modifier (SUMO)-interacting motif (SIM) of Oct4 is crucial for the interaction with ERG-associated pro- tein with SET domain (ESET) and the repression of Cdx2 Figure 6
Small ubiquitin-related modifier (SUMO)-interacting motif (SIM) of Oct4 is crucial for the interaction with 
ERG-associated protein with SET domain (ESET) and the repression of Cdx2. (a) Figure depicts SIM in Oct4 (top 
panel) and the mutations (red alphabet) in the Oct4-lacking SIM (-ΔSIM) (bottom panel). (b) Expression vectors indicated were 
transfected in 293T cells and immunoprecipitant (IP) from anti-Flag antibody and input were subjected to western blot (WB) 
with anti-haemagglutinin (HA) (ESET, top panel) and anti-Flag (Oct4 or Oct4-ΔSIM, bottom panel) antibodies. (c) Quantitative 
polymerase chain reaction (Q-PCR) analysis of Cdx2 (top), Oct4 (middle) and Eset (bottom) in ZHBTc4 ES cells that were 
either non-treated or treated with tetracycline (Tc) to deplete the endogenous Oct4 and transfected with the indicated plas-
mids, relative to control embryonic stem (ES) cells which was set as 1.0 (lane 1) after normalising against Gapdh. An empty vec-
tor was used as a transfection control in lane 2. Error bars represent standard deviation (SD) of the average and median of four 
different fractions of cells of different green fluorescent protein (GFP) intensity except for control ES cells (lane 1) where error 
bar represents the SD of three technical replicates.
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The proposed model of the establishment of pluripotent cells in the inner cell mass (ICM) through the repression of Cdx2 by  ERG-associated protein with SET domain (ESET)-Oct4 complex Figure 7
The proposed model of the establishment of pluripotent cells in the inner cell mass (ICM) through the repres-
sion of Cdx2 by ERG-associated protein with SET domain (ESET)-Oct4 complex.
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GATATATCCACTCACATCTTTTTA-3' and 5'-
AGCTTAAAAAGATGTGAGTGGATATATCGTCTCTT-
GAACGATATATCCACTCACATCGGG-3'. Sequences for
Pml shRNA which has also been described previously [34]
are 5'-GATCCCCGCGCAAGTCCAATATCTTCTTCAAGA-
GAGAAGATATTGGACTTGCGCTTTTTA-3' and 5'-
AGCTTAAAAAGCGCAAGTCCAATATCTTCTCTCTTGAA-
GAAGATATTGGACTTGCGCGGG-3'.
For construction of shRNA-poliovirus internal ribosomal
entry site (pIRES)-EGFP, pSuper.puro with or without
shRNA insert that has been digested with NotI and HincII
were ligated to pIRES-EGFP (Clontech, Mountain View,
CA, USA) that has been digested with NruI and NotI. For
transfection, 0.5 × 106 ES cells plated in 1 well of a 6-well
plate and cultured overnight were transfected with 3 μg of
plasmid using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA). Transfected cells were selected with 1
μg/ml puromycin (Sigma, St Louis, MO, USA) starting
from 24 h after transfection and cells were passaged upon
reaching confluency. For alkaline phosphatase staining,
western blot and analysis of the gene expression by Q-
PCR, cells were harvested on the indicated days without
undergoing fluorescence sorting. For morphology visuali-
sation, immunostaining and carrier ChIP analysis, trans-
fected cells were first sorted by FACS either 1 day (for
morphology visualisation) or 3 days after transfection. For
Pml knockdown experiments, immunostaining was per-
formed at day 5 after transfection and immunoprecipita-
tion was performed at day 4 after transfection.
Cell culture
Undifferentiated ES cells were cultured without feeders on
gelatin-coated culture dish in Dulbecco's modified Eagle
medium/F12 nutrient mixture without l-glutamine
(DMEM/F12) (Gibco, Carlsbad, CA, USA) supplemented
with 20% foetal bovine serum (Gibco, Carlsbad, CA,
USA), 2 mM l-glutamine (Gibco, Carlsbad, CA, USA), 0.1
mM minimal essential medium (MEM) with non-essen-
tial amino acids (Gibco, Carlsbad, CA, USA), 100 U/ml
penicillin and 0.1 mg/ml streptomycin (Gibco, Carlsbad,
CA, USA), 1 mM sodium pyruvate (Sigma, St Louis, MO,
USA), 0.12% sodium bicarbonate solution (Sigma, St
Louis, MO, USA), 50 μM 2-mercaptoethanol (Gibco,
Carlsbad, CA, USA), 0.15 mM of each nucleoside com-
prising adenosine, cytidine, guanosine and uridine and
0.05 mM of thymidine (Sigma, St Louis, MO, USA) and
2000 U/ml leukaemia inhibitory factor (Chemicon, Bill-
erica, MA, USA). ZHBTc4 ES cell cultures were as
described previously [18]. Oct4 expression was regulated
by the addition of 1 μg/ml doxycycline (Sigma, St Louis,
MO, USA) to the culture medium. TS cultures were as
described previously [13].
RNA extraction and real-time Q-PCR
Total RNA was prepared using RNeasy Mini Kit (Qiagen,
Hilden, Germany) and cDNA was synthesised from 1 μg
of RNA using SuperScript III reverse transcriptase (Invitro-
gen, Carlsbad, CA, USA). Endogenous mRNA levels were
measured by Q-PCR based on SYBR Green detection with
the ABI Prism 7000 PCR machine (Applied Biosystems,
Foster City, CA, USA). Each reaction in a total volume of
20 μl contained 1 μl of 10 × diluted cDNA, 1 μM of for-
ward and reverse primer and 1 × QuantiTect SYBR Green
Master Mix reagent (Qiagen, Hilden, Germany). Standard
curves for each primer were performed in the same sample
plate to determine the relative quantification of the tran-
script. Q-PCR was performed in triplicates and normal-
ised with Gapdh, a housekeeping gene. The data were then
normalised against vector control or untreated ES cells
which were defined as 100% or 1.0. Each experiment was
performed independently on at least two occasions.
Sequences of primers used for Q-PCR are available in
Additional file 8.
Protein extraction and immunoblot
Cell lysate was extracted using cold radioimmunoprecipi-
tation assay (RIPA) buffer consisting 50 mM
tris(hydroxymethyl)aminomethane (Tris) pH 8.0, 150
mM NaCl, 1% NP40, 0.5% sodium deoxycholate and
0.1% sodium dodecyl sulfate (SDS) added with protease
inhibitors (Roche, Basel, Switzerland) for 30 min on ice,
followed by centrifugation at 13,000 rpm for 30 min.
Supernatant was collected and protein concentration was
measured by Bradford assay (Sigma, St Louis, MO, USA).
Total protein (20 to 30 μg) was separated by Tris-glycine
SDS polyacrylamide gel and transferred to Hybond-P
poly(vinylidene difluoride) (PVDF) (Amersham, Buck-
inghamshire, UK) membrane. Proteins on polyacryla-
mide gel were visualised by staining with Imperial Protein
Stain (Pierce, Waltham, MA, USA).
Cotransfection and immunoprecipitation
Full details on vector constructions are available in Addi-
tional file 9. For cotransfection experiments, 3.5 × 106
293T cells plated on a 10 cm dish and cultured overnight
were transfected with 18 μg of DNA comprising of 9 μg of
two different constructs with Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA). Cells were harvested for
immunoprecipitation 48 h after transfection. Cells were
washed twice in cold phosphate-buffered saline (PBS) and
scraped into 1 ml of PBS. Cell pellet were resuspended in
200 μl of immunoprecipitation buffer (50 mM Tris pH
7.5, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid
(EDTA), 15 mM MgCl2, 0.75% sodium deoxycholate and
1% NP40 added with protease inhibitors from Roche,
Basel, Switzerland), incubated on ice for 30 min and cen-
trifuged at 13,000 rpm for 30 min at 4°C. A total of 100
μl of the supernatant was then diluted with 900 μl dilu-Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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tion buffer (50 mM Tris pH 7.5 and 150 mM NaCl added
with protease inhibitor from Roche, Basel, Switzerland)
so that the final concentration of NP40 in the immuno-
precipitation reaction was 0.1%. The primary antibody
was incubated with the protein lysate at 4°C overnight.
Precipitation was performed by adding 50 μl of Dyna-
beads Protein G (Invitrogen, Carlsbad, CA, USA) to the
reaction for 1 h followed by five washes in buffer contain-
ing 50 mM Tris pH 8.0, 150 mM NaCl and 0.1% NP40.
Beads were boiled for 5 min with 50 μl 2 × Laemmli sam-
ple buffer (Bio-Rad, Hercules, CA, USA) and 20 μl of the
supernatant were subjected to western blot. Where indi-
cated, lysis buffer was also added with 20 mM NEM
(Sigma, St Louis, MO, USA) and 1:100 diluted phos-
phatase inhibitors I and II (Sigma, St Louis, MO, USA).
Endogenous immunoprecipitation
To analyse SUMOylated ESET, one confluent 10 cm dish
of ES cells was lysed in 100 μl buffer containing 50 mM
Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 15 mM MgCl2,
0.75% sodium deoxycholate, 1% NP40 supplemented
with protease inhibitors (Roche, Basel, Switzerland),
1:100 diluted phosphatase inhibitors I and II (Sigma, St
Louis, MO, USA) and 20 mM NEM (Sigma, St Louis, MO,
USA). Where indicated, lysis buffer was also added with
50 μg/ml of ethidium bromide. Cell lysate was incubated
on ice for 30 min and centrifuged at 13,000 rpm for 30
min at 4°C. A total of 100 μl of the supernatant were then
diluted with 900 μl dilution buffer (50 mM Tris pH 7.5
and 150 mM NaCl added with the protease inhibitors
(Roche, Basel, Switzerland), 1:100 diluted phosphatase
inhibitors I and II (Sigma, St Louis, MO, USA) and 20 mM
NEM (Sigma, St Louis, MO, USA). Cell lysate was pre-
cleared with 25 μl Dynabeads Protein G (Invitrogen,
Carlsbad, CA, USA) for 1 h at 4°C and centrifuged at
13,000 rpm for 20 min at 4°C. The primary antibody was
incubated with the supernatant at 4°C overnight. Precipi-
tation was performed by the addition of 50 μl of Dyna-
beads Protein G to the reaction for 1 h followed by five
washes in immunoprecipitation buffer as described
above. Beads were resuspended in 35 μl of immunopre-
cipitation buffer and 45 μl of 2 × Laemmli sample buffer
(Bio-Rad, Hercules, CA, USA). After boiling for 5 min, 20
μl of the supernatant were subjected to western blot using
4% to 15% Tris-HCl gradient gel (Bio-Rad, Hercules, CA,
USA). For immunoprecipitation in mild conditions
(where indicated), lysis and immunoprecipitation buffer
consist of 50 mM Tris-HCl pH 7.5, 150 mM NaCl and
0.3% digitonin (Sigma, St Louis, MO, USA) supple-
mented with protease inhibitors (Roche, Basel, Switzer-
land), 1:100 diluted phosphatase inhibitors I and II
(Sigma, St Louis, MO, USA) and 20 mM NEM (Sigma, St
Louis, MO, USA). Wash buffer consists of the same com-
ponents as immunoprecipitation buffer except that 50
mM NaCl was used.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed accord-
ing to a published protocol [35] with some modifications.
Briefly, cells were crosslinked with 1/10 volume of fresh
11% formaldehyde solution for 15 min and quenched
with 1/20 volume of 2.5 M glycine. Cells were sonicated
to an average of 500 base pairs (bp) and immunoprecipi-
tated overnight with antibody that was preincubated with
100 μl Dynabeads M-280 Sheep Anti-Rabbit (Invitrogen,
Carlsbad, CA, USA) overnight. For isolation of DNA, 100
μl of 10% Chelex (w/v) was added to the washed beads,
vortexed and boiled for 10 min [36]. After cooling to
room temperature, 100 μg/ml of proteinase K was added
and beads were incubated for 30 min at 55°C in a shaking
block. Beads were boiled for another 10 min, centrifuged,
and the supernatant was collected. The Chelex/bead frac-
tion was vortexed with another 100 μl of water, centri-
fuged and the supernatant collected was combined with
the first supernatant. Immunoprecipitated DNA (3 μl)
was used as template for PCR amplification with Red Taq
(Sigma, St Louis, MO, USA) or 1 to 2 μl was used for Q-
PCR analysis using 1 × QuantiTect SYBR Green Master Mix
reagent (Qiagen, Hilden, Germany). Data were normal-
ised to the input or H3 ChIP, control IgG and the least
enriched region (as indicated in the figure legends). To
compare the enrichment of H3K9me3 between samples,
carrier ChIP was performed by adding 3 × 107 293T cell to
1 × 106 FACS-sorted, EGFP-positive ES cells transfected
with either Eset  shRNA or empty vector for 3 days
(selected with puromycin for 2 days). Carrier ChIP of
H3K9me3 was also performed in Figure 3d. Immunopre-
cipitated DNA was concentrated by ethanol precipitation
before PCR analysis. Data were normalised against the
input and relative to the controls. Semi quantification of
band intensity was performed using Quantity One soft-
ware (Bio-Rad, Hercules, CA, USA). ChIP experiments
were performed independently on at least two occasions.
Primers and PCR conditions for ChIP are available in
Additional file 10.
Mutagenesis and transfection
Oct4-ΔSIM construct was generated using the Quik-
Change XL Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA). Details on the construct are available in
Additional file 9. For transfection, 0.5 × 106 ZHBTc4 ES
cells plated on 1 well of a 6-well plate and cultured over-
night were transfected with 3 μg of plasmid using Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
Doxycycline 1 μg/ml (Sigma, St Louis, MO, USA) was
added to the culture medium after 6 h of transfection to
remove the endogenous Oct4. Transfected cells were
sorted by FACS after 48 h of transfection.Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
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Immunofluorescence microscopy
Single cells on poly-l-lysine (Sigma, St Louis, MO, USA)
treated 12 well microscope slides (Erie Scientific Com-
pany, Waltham, MA, USA) were centrifuged at 1,000 rpm
for 1 min and fixed with 4% paraformaldehyde (Sigma, St
Louis, MO, USA) in PBS for 15 min. This was followed by
three washes in PBS and blocking and permeabilisation in
0.1% Triton X (v/v) and 1% bovine serum albumin (BSA)
(w/v) in PBS for 30 min. Primary antibodies diluted in
blocking buffer were incubated at 4°C overnight. Second-
ary antibodies conjugated to Alexa Fluor 488 and 568
(Molecular Probes, Carlsbad, CA, USA) and DAPI (1 μg/
ml) were incubated at room temperature, in the dark for
1 h. Cells were mounted on slides with Vectashield (Vec-
tor Laboratories, Burlingame, CA, USA) containing DAPI
and images were captured with a Bio-Rad Radiance 2000
confocal microscope.
Antibodies
Antibodies used for western blot were; ESET (07-378,
Upstate, Billerica, MA, USA), α-tubulin (T9026, Sigma, St
Louis, MO, USA), H3K9me3 (07-442, Upstate, Billerica,
MA, USA), H3K4me2 (ab7766, Abcam, Cambridge, UK),
Oct-3 (611202, BD, Franklin Lakes, NJ, USA), Cdx2 (Bio-
genex, San Ramon, CA, USA), SUMO-1 (Affinity Biorea-
gents, Waltham, MA, USA), PML (05-718, Upstate,
Billerica, MA, USA) Anti-Flag (F3165, Sigma, St Louis,
MO, USA) and Anti-HA (ab9110; Abcam, Cambridge,
UK). Antibodies used for immunoprecipitation were;
ESET (ab12317, Abcam, Cambridge, UK), (kind gift from
HH Ng, Genome Institute of Singapore, Singapore) and
(sc-46110, Santa Cruz, Santa Cruz, CA, USA), SUMO-1
(Affinity Bioreagents, Waltham, MA, USA), PML (sc-5621,
Santa Cruz, Santa Cruz, CA, USA), Oct4 (sc-9081, Santa
Cruz, Santa Cruz, CA, USA), Anti-Flag (F3165, Sigma, St
Louis, MO, USA) and Anti-HA (ab9110; Abcam, Cam-
bridge, UK).
Antibodies used for chromatin immunoprecipitation
were; H3K9me3 (ab8898; Abcam, Cambridge, UK), ESET
(kind gift from HH Ng, Genome Institute of Singapore),
Oct4 (sc-9081, Santa Cruz, Santa Cruz, CA, USA), SUMO-
1 (Zymed, Carlsbad, CA, USA), Anti-Flag (F3165, Sigma,
St Louis, MO, USA) and Anti-HA (ab9110; Abcam, Cam-
bridge, UK). Antibodies used for immunofluorescence
were Cdx2 (1:100, Biogenex, San Ramon, CA, USA), ESET
(1:100, 07-378, Upstate, Billerica, MA, USA) and PML
(1:200, 05-718, Upstate, Billerica, MA, USA).
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Additional material
Additional file 1
Eset is required for normal embryonic stem (ES) cell phenotype. (a) 
Alkaline phosphatase staining of Eset knockdown (right panel) and con-
trol (left panel) ES cells after 7 days of short hairpin RNA (shRNA) trans-
fection. Scale bar, 100 μm. (b) Morphology of Eset knockdown and 
control ES cells after 3 days of shRNA transfection from both EGFP-posi-
tive (transfected) and EGFP-negative (untransfected) populations. Scale 
bar, 100 μm. Inset, 50 μm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S1.PDF]
Additional file 2
ERG-associated protein with SET domain (ESET)-mediated histone 3 
lysine 9 trimethylation (H3K9me3) represses Cdx2 in embryonic stem 
(ES) cells. (a) Semiquantitative polymerase chain reaction (PCR)-chro-
matin immunoprecipitation (ChIP) analysis of H3K9me3 at the Cdx2 
and Oct4 promoter regions in ES cells. (b) Carrier ChIP semiquantitative 
PCR analysis of H3K9me3 in fluorescence-activated cell sorting (FACS)-
sorted Eset knockdown ES cells (+) and control ES cells (-). 293T cells 
were added as carrier. H3K9me3 levels were downregulated at the Cdx2 
promoter region (top panel, lane 4). No signal was detected in carrier 
cells, 293T input (lane 7) showing specificity of PCR to mouse genomic 
DNA. Primers C6 and C7 were not specific to mouse DNA. H3K9me3 
was not detected at the control Oct4 promoter region (middle panel). 
Suv39h1/2-mediated H3K9me3 level at the major satellite region was 
unaffected in ESET-depleted ES cells (bottom panel).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S2.PDF]
Additional file 3
ERG-associated protein with SET domain (ESET) binding to Cdx2 
promoter is dependent on Oct4 through Oct4-ESET interaction. (a) 
Quantitative polymerase chain reaction (Q-PCR) analysis of the levels of 
haemagglutinin (HA)-ESET enrichment at region C7 of the Cdx2 pro-
moter in ZHBTc4 embryonic stem (ES) cells, which were first treated with 
tetracycline, followed 1 day later by transfection of HA-ESET. At 1 day 
after transfection (day 2 of tetracycline treatment), cells were harvested 
for ChIP experiments. HA-ESET enrichment on day 2 of tetracycline 
treatment is relative to untreated cells after normalising against ZHBTc4 
ES cells transfected with an empty vector, and their respective input. Error 
bars, standard deviation (SD) of three technical replicates. (b) Coimmu-
noprecipitation of ESET with Oct4 in 293T cells. Expression vectors indi-
cated were transfected and Flag-tagged Oct4 protein was 
immunoprecipitated. Immunoprecipitant (IP) and supernatant were sub-
jected to western blot (WB) with anti-HA (ESET, top panel) and anti-
Flag (Oct4, bottom panel) antibodies. HA, haemagglutinin. (c) Draw-
ings depicting full length ESET and ESET mutant proteins. Numbers indi-
cate amino acids. (d) Coimmunoprecipitation of ESET-ΔSET and ESET-
ΔTudor with Oct4 in 293T cells. Expression vectors indicated were trans-
fected and Flag-tagged Oct4 protein was immunoprecipitated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
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Additional file 5
ERG-associated protein with SET domain (ESET) interacts with pro-
myelocytic leukaemia (PML). (a) Coimmunoprecipitation of PML with 
ESET in 293T cells. Immunoprecipitant (IP) and supernatant were sub-
jected to western blot (WB) with anti-Flag (PML, top panel) and anti-
haemagglutinin (HA) (ESET, bottom panel) antibodies. (b) Embryonic 
stem (ES) cell lysates were immunoprecipitated (IP) with the indicated 
antibodies in buffer containing NP40 in the presence of N-ethylmaleim-
ide (NEM) and subjected to WB using 4% to 15% Tris-HCl gradient gel. 
A rabbit anti-HA antibody was used as a negative control.
Click here for file
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Additional file 6
Putative small ubiquitin-related modifier (SUMO)ylation sites of 
ERG-associated protein with SET domain (ESET) based on the 
SUMOplot software. Red triangles represent motifs with high probability 
and blue triangles represent motifs with low probability.
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Additional file 7
Mutation of Oct4 SIM does not affect its ability to bind DNA. (a) 
Quantitative polymerase chain reaction (Q-PCR) analysis of the levels of 
Flag-tagged enrichment at region O1 of the Oct4 promoter in ZHBTc4 
ES cells transfected with Flag-Oct4 or Flag-Oct4-ΔSIM relative to controls 
transfected with an empty vector after normalising against their respective 
input. Tetracycline was added to the culture medium 6 h after transfection 
to deplete endogenous Oct4. Cells were harvested at 48 h after transfec-
tion. Error bars, standard deviation (SD) of three technical replicates. (b) 
Q-PCR analysis of Gata6 (top), Dlx3 (middle) and Hand1 (bottom) in 
ZHBTc4 embryonic stem (ES) cells; these cells were treated with tetracy-
cline (Tc+) to deplete the endogenous Oct4, or left untreated (Tc-). They 
were transfected with the indicated control or mutant Oct4 plasmids. 
Gene expression levels are relative to control ES cells which was set as 1.0 
(lane 1) after normalising against Gapdh. An empty vector was used as 
a transfection control in lane 2. Error bars represent SD of the average and 
median of four different fractions of cells of different GFP intensity except 
for control ES cells (lane 1) where error bar represents the SD of three 
technical replicates.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S7.PDF]
Additional file 8
Table S1. Quantitative polymerase chain reaction (Q-PCR) Primers
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S8.DOC]
Additional file 9
Supplementary methods. Overexpression constructs
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S9.DOC]
Additional file 10
Table S2. Chromatin Immunoprecipitation (ChIP) Primers
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-12-S10.DOC]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Epigenetics & Chromatin 2009, 2:12 http://www.epigeneticsandchromatin.com/content/2/1/12
Page 17 of 17
(page number not for citation purposes)
entiation markers in human and mouse embryonic stem
cells.  Stem Cells 2004, 22:225-235.
11. Beddington RS, Robertson EJ: An assessment of the develop-
mental potential of embryonic stem cells in the midgesta-
tion mouse embryo.  Development 1989, 105:733-737.
12. Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R,
Rossant J: Interaction between Oct3/4 and Cdx2 determines
trophectoderm differentiation.  Cell 2005, 123:917-929.
13. Tanaka S, Kunath T, Hadjantonakis A-K, Nagy A, Rossant J: Promo-
tion of trophoblast stem cell proliferation by FGF4.  Science
1998, 282:2072-2075.
14. Strumpf D, Mao C-A, Yamanaka Y, Ralston A, Chawengsaksophak K,
Beck F, Rossant J: Cdx2 is required for correct cell fate specifi-
cation and differentiation of trophectoderm in the mouse
blastocyst.  Development 2005, 132:2093-2102.
15. Lehnertz B, Ueda Y, Derijck AAHA, Braunschweig U, Perez-Burgos L,
Kubicek S, Chen T, Li E, Jenuwein T, Peters AHFM: Suv39h-medi-
ated histone H3 lysine 9 methylation directs DNA methyla-
tion to major satellite repeats at pericentric
heterochromatin.  Curr Biol 2003, 13:1192-1200.
16. Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer
C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S,
Doyle M, Sibilia M, Jenuwein T: Loss of the Suv39h histone meth-
yltransferases impairs mammalian heterochromatin and
genome stability.  Cell 2001, 107:323-337.
17. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G,
George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD,
Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL,
Ruan Y, Lim B, Ng HH: The Oct4 and Nanog transcription net-
work regulates pluripotency in mouse embryonic stem cells.
Nat Genet 2006, 38:431-440.
18. Niwa H, Miyazaki J, Smith AG: Quantitative expression of Oct-3/
4 defines differentiation, dedifferentiation or self-renewal of
ES cells.  Nat Genet 2000, 24:372-376.
19. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guen-
ther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA,
Jaenisch R, Young RA: Core transcriptional regulatory circuitry
in human embryonic stem cells.  Cell 2005, 122:947-956.
20. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca
M ,  L a m o n d  A ,  D e j e a n  A :  Retinoic acid regulates aberrant
nuclear localization of PML-RARα in acute promyelocytic
leukemia cells.  Cell 1994, 76:345-356.
21. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM: A
novel macromolecular structure is a target of the promyelo-
cyte-retinoic acid receptor oncoprotein.  Cell 1994, 76:333-343.
22. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh
ETH:  Identification of three major sentrinization sites in
PML.  J Biol Chem 1998, 273:26675-26682.
23. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP:
Role of SUMO-1-modified PML in nuclear body formation.
Blood 2000, 95:2748-2752.
24. Muller S, Matunis MJ, Dejean A: Conjugation with the ubiquitin-
related modifier SUMO-1 regulates the partitioning of PML
within the nucleus.  EMBO J 1998, 17:61-70.
25. Shen TH, Lin H-K, Scaglioni PP, Yung TM, Pandolfi PP: The mecha-
nisms of PML-nuclear body formation.  Mol Cell 2006,
24:331-339.
26. Sampson DA, Wang M, Matunis MJ: The small ubiquitin-like mod-
ifier-1 (SUMO-1) consensus sequence mediates Ubc9 bind-
ing and is essential for SUMO-1 modification.  J Biol Chem 2001,
276:21664-21669.
27. Hannich JT, Lewis A, Kroetz MB, Li S-J, Heide H, Emili A, Hoch-
strasser M: Defining the SUMO-modified proteome by multi-
ple approaches in Saccharomyces cerevisiae.  J Biol Chem 2005,
280:4102-4110.
28. Hecker C-M, Rabiller M, Haglund K, Bayer P, Dikic I: Specification
of SUMO1- and SUMO2-interacting motifs.  J Biol Chem 2006,
281:16117-16127.
29. Minty A, Dumont X, Kaghad M, Caput D: Covalent modification
of p73α by SUMO-1. Two-hybrid screening with p73 identi-
fies novel SUMO-1-interacting proteins and a SUMO-1 inter-
acting motif.  J Biol Chem 2000, 275:36316-36323.
30. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y: Identifica-
tion of a SUMO-binding motif that recognizes SUMO-modi-
fied proteins.  Proc Natl Acad Sci USA 2004, 101:14373-14378.
31. Kim J, Chu J, Shen X, Wang J, Orkin SH: An extended transcrip-
tional network for pluripotency of embryonic stem cells.  Cell
2008, 132:1049-1061.
32. Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY, Qin J, Wong J, Cooney
AJ, Liu D, Songyang Z: Nanog and Oct4 associate with unique
transcriptional repression complexes in embryonic stem
cells.  Nat Cell Biol 2008, 10:731-739.
33. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M,
Babinet C, Pandolfi PP, Dejean A: The SUMO pathway is essential
for nuclear integrity and chromosome segregation in mice.
Dev Cell 2005, 9:769-779.
34. Park SW, Hu X, Gupta P, Lin Y-P, Ha SG, Wei L-N: SUMOylation
of Tr2 orphan receptor involves Pml and fine-tunes Oct4
expression in stem cells.  Nat Struct Mol Biol 2007, 14:68-75.
35. Lee TI, Johnstone SE, Young RA: Chromatin immunoprecipita-
tion and microarray-based analysis of protein location.  Nat
Protocols 2006, 1:729-748.
36. Nelson JD, Denisenko O, Sova P, Bomsztyk K: Fast chromatin
immunoprecipitation assay.  Nucl Acids Res 2006, 34:e2.